Trends Neurosci by Chow, Brian Wai & Gu, Chenghua
The molecular constituents of the blood-brain barrier
Brian Wai Chow and Chenghua Gu
Department of Neurobiology, Harvard Medical School, 220 Longwood Ave, Boston, 
Massachusetts 02115, USA
Abstract
The blood-brain barrier (BBB) maintains the optimal microenvironment in the central nervous 
system (CNS) for proper brain function. The BBB is comprised of specialized CNS endothelial 
cells with fundamental molecular properties essential for the function and integrity of the BBB. 
The restrictive nature of the BBB hinders delivery of therapeutics for many neurological disorders. 
In addition, recent evidence shows that BBB dysfunction can precede or hasten the progression of 
several neurological diseases. Despite the physiological significance of the BBB in health and 
disease, major discoveries of the molecular regulators of BBB formation and function have only 
occurred recently. This review will highlight recent findings describing the molecular 
determinants and core cellular pathways that confer BBB properties upon CNS endothelial cells.
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History of the blood-brain barrier
The BBB partitions the brain from circulating blood and functions to a) shield the brain from 
potential blood-borne toxins, b) meet the metabolic demands of the brain, and c) regulate the 
homeostatic environment in the CNS for proper neuronal function[1]. The functional BBB is 
comprised of CNS endothelial cells, pericytes, astrocytes and neurons that collectively form 
a functional “neurovascular unit” (NVU)(Figure 1) [2].
The BBB was first observed over a century ago. Pioneering physiologists studying the 
cerebrospinal fluid (CSF) noticed that water-soluble dyes injected in the peripheral 
circulation stained several tissues except the brain[3]. Ehrlich argued that this phenomenon 
occurred because the CNS had low affinity for the dye[4]. However, Goldmann questioned 
this argument, as injection of the same dyes in the subarachnoid space colored the brain but 
not peripheral tissues[5]. Continuing from these studies, Lina Stern and colleagues 
performed experiments in which they injected several vehicles into the brain parenchyma 
and blood. The results from these dye studies prompted Stern to introduce the term, “blood-
brain barrier” and suggest its physiological function in maintaining brain homeostasis[6]. 
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Over the years, the concept of the BBB fascinated physiologists but the anatomical site of 
the BBB was highly disputed; specific possibilities included the endothelium, astrocytic 
end-feet, or the basement membrane. A seminal study by Reese and Karnovsky using 
electron microscopy (EM) and injection of electron-dense horseradish peroxidase (HRP) 
resolved this dispute [7]. In this work, ultrastructural analysis by EM was used to delineate 
astrocytic end-feet, and the luminal, abluminal, and basement membrane. Results revealed 
that the HRP was confined to the lumen of the CNS endothelium. Furthermore, EM revealed 
that the CNS endothelial cells are joined continuously by tight junction complexes and have 
limited intracellular vesicles[7]. Similar to Goldman’s experiments, HRP injection into the 
brain parachyma diffused past astrocytic end-feet and halted at the abluminal membrane of 
the endothelium, demonstrating that astrocytic end-feet do not significantly contribute to the 
physical barrier[8]. Thus, the site of the BBB is CNS capillaries comprised of a single, non-
fenestrated, continuous endothelial cell layer.
Molecular properties of the BBB
CNS endothelial cells are highly polarized with distinct luminal (apical) and abluminal 
(basolateral) compartments[9]. The polarized nature of CNS endothelial cells is reflected in 
their four fundamental barrier properties that contribute to BBB function and integrity 
(Figure 2)[10]. First, circumferential tight junction complexes at the lateral, apical 
membrane between CNS endothelial cells establish a high-resistance paracellular barrier to 
small hydrophilic molecules and ions[8,11]. Tight junction complexes are comprised of a) 
tight junction proteins such as claudins and occludin, b) adhesion molecules such as VE-
cadherin and E-cadherin and c) junctional adhesion molecules[12,13]. These transmembrane 
proteins are further linked and stabilized to the cytoskeleton via multiple cytoplasmic 
adaptor proteins such as zonula occludens proteins [14]. Emerging studies have 
demonstrated that there is significant crosstalk among these tight junction complex proteins 
to regulate the restrictive barrier junction[15]. Second, in contrast to the peripheral 
endothelium, CNS endothelial cells display minimal vesicular trafficking, limiting the 
vesicle-mediated transcellular movement of cargo known as transcytosis[16]. Although CNS 
endothelial cells display limited transcytosis, it is still the preferred pathway for the selective 
transport of plasma macromolecules such as albumin and low-density lipoprotein[17]. Third, 
the establishment of the restrictive paracellular and transcellular barriers allows CNS 
endothelial cells to use highly polarized cellular transporters to dynamically regulate the 
influx of nutrients and efflux of metabolic waste and toxins between the blood and the brain 
parenchyma. The major class of known efflux transporters is the ATP-binding cassette 
(ABC) transporters- including Pgp, BCRP and MRP- mostly localized at the luminal 
membrane[18–20]. These efflux transporters hydrolyze ATP to transport a wide array of 
substrates against their concentration gradients into the blood[19,20]. CNS endothelial cells 
also express specialized nutrient transporters that facilitate the transport of ions, 
macromolecules and proteins from the blood to the brain. Many of these transporters belong 
to the superfamily solute carrier proteins (SLC) of facilitative transporters that includes 
sugar transporters such as SLC2A1 (GLUT1), and cationic amino acid transporters such as 
SLC7A1 [21,22]. It is surprising to note that although SLCs play a vital role in metabolism 
and nutrition, they are particularly understudied[23]. Fourth, CNS endothelial cells lack the 
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expression of leukocyte adhesion molecules (LAMs) such as E-selectin and Icam1[24]. The 
lack of these luminal surface molecules prevents the entry of immune cells from the blood 
into the parenchyma, resulting in a paucity of immune cells in the brain 
microenvironment[25]. As a result, the healthy brain is “immune privileged”, where 
introduced antigens do not elicit the development of adaptive immune responses[26]. These 
fundamental molecular characteristics confer BBB properties on CNS endothelial cells to 
regulate brain homeostasis.
Identifying molecular regulators of BBB function and integrity in CNS 
endothelial cells
The four fundamental BBB properties listed above are not intrinsic to CNS endothelial cells 
but are induced and regulated by the neural environment[27]. Transplantation studies using 
chick/quail chimeras have demonstrated that nonvascularized brain fragments transplanted 
into the coelomic cavity were soon vascularized by abdominal vessels that developed BBB 
characteristics, such as exclusion of circulating dye and low number of vesicles[28]. In 
contrast, nonvascularized embryonic mesoderm tissues grafted in the CNS were soon 
vascularized by neural vessels that failed to displayed BBB properties[28]. This seminal 
experiment demonstrated that: 1) BBB properties are not inherent to CNS endothelial cells 
and 2) the neural environment provides inductive cues to CNS endothelial cells to activate 
genetic programs in order to acquire BBB properties. Although the identities of these signals 
and genetic programs have been elusive, recent advances in purification and gene expression 
profiling of CNS endothelial cells have elucidated novel molecular mediators that confer 
barrier properties upon CNS endothelial cells.
The most well-characterized genetic program inducing BBB properties in CNS endothelial 
cells (Table 1a) is β-catenin signaling[29–31]. Daneman et al. purified CNS and peripheral 
endothelial cells using fluorescence-activated cell sorting (FACS) from Tie2GFP mice, a 
transgenic GFP reporter for endothelial cells[31]. Microarray analysis indicated that many 
downstream effectors of Wnt/ β-catenin signaling are enriched in CNS endothelial cells, 
suggesting that β-catenin signaling may mediate CNS vasculature functions. Indeed, various 
studies have demonstrated that canonical Wnt signaling is essential for both CNS-specific 
angiogenesis and barriergenesis. For example, endothelial cell specific deletion of β-catenin 
disrupts CNS-angiogenesis, resulting in gross vascular malformations and hemorrhages 
whereas peripheral angiogenesis remains largely undisrupted[31]. In addition, endothelial 
cell-specific deletion of β-catenin disrupts barriergenesis, downregulating Glut1 expression, 
a marker commonly used for BBB formation, in CNS vasculature[29–31]. Zhou et al. [28] 
demonstrated that postnatal, endothelial cell-specific deletion of β-catenin results in BBB 
breakdown, exemplified by extravasation of dyes and downregulation of tight junction 
protein expression, showing that barrier dysfunction is not a consequence of disrupted 
angiogenesis. Recently, many of the receptors upstream of B-catenin - including Frizzled 
receptors, co-receptors LRP5 /LRP6 and auxiliary receptor GPR124 - as well as the Wnt 
ligands (please see next section) necessary for β-catenin activation have been identified[32–
40]. Loss-of-functions of these genes results in CNS vasculature dysfunction and largely 
resembles β-catenin mutants[33,34].
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A recent study identified novel downstream targets of β-catenin signaling that mediate both 
CNS angiogenesis and barriergenesis. Tam et al. used antibody-based FACS to isolate 
endothelial cells from CNS and non-CNS tissues at three developmental ages.[41] 
Microarray analysis indicated dr6, troy and spock2 are highly enriched in CNS endothelial 
cells. Indeed, these genes are essential for CNS vasculature function as dr6, troy and spock2 
knockdown in zebrafish resulted in vascular malformation and barrier dysfunction. In 
contrast, loss-of-function of other genes enriched in CNS endothelial cells, abcyap1r1 and 
tspn5, resulted in vascular morphogenesis defects but exhibited no barrier dysfunction. The 
authors demonstrated that in vitro activation of β-catenin with recombinant Wnt ligands 
upregulates the expression of dr6 and troy, suggesting that these genes are downstream 
effectors of β-catenin. However, it is difficult to determine if these genes specifically 
regulate barriergenesis, or if barrier dysfunction is a consequence of vascular malformations. 
Temporal deletion of these genes after CNS angiogenesis can clarify this point.
Genes that specifically regulate BBB function and integrity independent of CNS 
angiogenesis have been identified via gene profiling of purified CNS endothelial cells. Ben-
Zvi et al. mapped the development of mouse cortical barriergenesis at E15.5 and performed 
microarray analysis from FACS purified Tie2GFP+ CNS and lung endothelial cells at 
E13.5, a time when barrier properties are actively forming[42]. The microarray analysis 
indicated that major facilitator domain containing protein 2A (Mfsd2a) is enriched in CNS 
endothelial cells. Mfsd2a is expressed specifically in CNS vasculature and not in the choroid 
plexus, a structure that lacks BBB. Mfsd2a knockout mice display BBB dysfunction due to 
unregulated bulk flow of transcytosis. However, vascular development and patterning 
remain unaffected, suggesting Mfsd2a specifically regulates BBB integrity independent of 
angiogenesis. Surprisingly, Mfsd2a has putative dual physiological functions[43,44]. Not 
only is Mfsd2a essential for the CNS endothelium to maintain low rates of transcytosis, but 
also Nguyen et al. reported that Mfsd2a is a transporter for omega-3 fatty acids across the 
CNS endothelium[45]. Lipidomics revealed that brains of Mfsd2a knockout mice exhibit 
decreased docosahexaenoic acid (DHA), an omega-3 fatty acid essential for neuronal 
function, and elevated arachidonic acid, an omega-6 fatty acid. Furthermore, Mfsd2a 
knockout mice display fewer neurons in the hippocampus and cerebellum, microcephaly and 
other neurological deficits. These altered brain fatty acids and behavioral abnormalities are 
reminiscent of omega-3 fatty acid deficiency[46]. In fact, recent human genetics studies 
identified loss-of-function missense mutations in MFSD2A as a recessive cause of 
microcephaly [47,48]. One study identified two MFSD2A missense mutations that result in 
severe intellectual disability, seizures and early lethality, whereas a second study identified a 
milder MFSD2A missense mutation that results in patients with intellectual disability alone. 
Similar to GLUT1, Mfsd2a has dual physiological functions at the BBB – maintaining 
barrier integrity and transporting nutrients across the barrier[49,50]. It will be essential for 
future studies to determine if Mfsd2a’s dual physiological functions of (1) maintaining BBB 
integrity and (2) transporting essential nutrients act simultaneously or if one function is 
required for the other.
Another recently discovered gene that mediates barriergenesis independent of angiogenesis 
is lipolysis-stimulated lipoprotein receptor (LSR). Sohet and Daneman et al. also purified 
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TIE2GFP+ CNS and peripheral endothelial cells and performed microarray analysis to 
identify lsr, another gene enriched in CNS endothelial cells[51,52]. Although lsr is 
expressed in many cell-types in peripheral tissues, it is expressed specifically in endothelial 
cells in the brain. LSR was initially reported to mediate clearance of triglyceride-rich 
lipoproteins and low-density lipoproteins but the physiological function of LSR in BBB was 
just recently explored[53]. Lsr knockout mice were reported not to display any vascular 
malformations or hemorrhage but still display BBB dysfunction. Indeed, LSR is essential for 
BBB integrity, as lsr knockout embryos exhibit extravasation of small molecular weight 
tracers but not larger molecular weight tracers, a phenotype that is reminiscent of the 
claudin5 knockout mouse[54]. This size selective permeability dysfunction may be a 
common phenotype observed when disrupting tight junction molecules. The extravasation of 
small tracers is most likely mediated via paracellular entry. In contrast, larger molecules 
most likely leak out through transcytosis, such as observed in Mfsd2a knockout mice, where 
HRP (44 kDa) and 70 kDa dextran tracers leak out of the CNS vasculature. However, the 
molecular mechanism underlying LSR regulation of BBB integrity is still unknown. 
Although LSR is localized at the tricellular tight junctions (where two bicellular tight 
junctions meet) in the functional BBB, lsr knockout mice display no obvious disruption in 
TJ complexes by EM. Because lsr has known physiological functions in peripheral tissues, 
conditional deletion of LSR will determine if a cell autonomous function of LSR regulates 
BBB integrity.
Identifying inductive signals that confer BBB properties
Recent studies have identified key inductive signals in the CNS microenvironment that 
confer CNS endothelial cells with BBB properties (Table 1b). It is evident that these 
inductive signals originate from the NVU. As mentioned above, the most well-characterized 
signal that mediates BBB function is canonical Wnt signaling[29–31,33]. Neural progenitors 
in the neuroepithelium secrete Wnt7a/Wnt7b, whereas in the cerebellum, Bergmann glia 
secrete Norrin. These secreted ligands bind to classical components of canonical Wnt 
signaling such as the Frizzled receptors and co-receptors LRP5 /LRP6 that are expressed on 
CNS endothelial cells to drive β-catenin signaling. Disruption of these Wnt ligands 
phenocopies β-catenin mutants, impairing CNS angiogenesis and displaying loss of vessel 
numbers, vascular malformations, hemorrhages, and BBB dysfunction[31–33].
Another inductive signal essential for barriergenesis is Sonic hedgehog (Shh) signaling. 
Although Hedgehog signaling has been well-characterized for neuronal development and 
angiogenesis, Alvarez et al. demonstrated that astrocyte-secreted Shh is essential for BBB 
integrity and CNS immune quiescence[55,56]. Astrocytes express shh whereas CNS 
endothelial cells robustly express Hedgehog signaling components-Patched-1, Smoothened 
and Gil. Astrocyte-conditioned medium or recombinant Shh were sufficient to (a) elevate 
tight junction protein expression and transendothelial electrical resistance (TEER), a 
technique used to measure the integrity of tight junctions dynamics in cell culture, and (b) 
suppress permeability of various tracers in vitro. Furthermore, endothelial cell-specific 
disruption of Hedgehog signaling in vivo results in normal vascular formation but BBB 
dysfunction through suppressed expression of tight junction proteins and extravasation of 
plasma proteins. Hedgehog signaling is also essential to establish immune quiescence in the 
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CNS. For example, Hedgehog signaling is sufficient to suppress chemokines and LAM 
expression in ECs in vitro. Furthermore, Hedgehog signaling in leukocytes suppresses 
expression of proinflammatory cytokines, such as Tumor Necrosis Factor (TNF), reducing 
neuroinflammatory processes. Hedgehog signaling has a protective role in 
neuroinflammatory diseases such as Multiple Sclerosis (MS). MS patients display elevated 
Hedgehog signaling components in the CNS and pharmacological blockade of Hedgehog 
signaling in EAE models results in greater severity of the disease, with increases in 
proinflammatory cytokines, leukocyte accumulation in the CNS and demyelination. It 
should be noted that the above studies focus on Hedgehog signaling as essential for BBB 
maintenance, not necessarily induction, as astrocytes are born and manifest in the NVU 
around birth. Although Shh is robustly expressed in the CNS during embryonic development 
and Shh knockout mice display reduced tight junction expression at E13.5, shortly before 
BBB maturation, the early roles of Hedgehog signaling during barriergenesis is still not 
well-characterized. Therefore, it will be interesting to explore the early inductive roles of 
Shh during BBB development before the onset of astrocyte-mediated Shh signaling to 
maintain BBB integrity.
Although it is well established that the neural microenvironment contains factors that induce 
CNS endothelial cells to manifest BBB properties, recent studies demonstrate that 
environmental cues and factors extrinsic to the CNS can impact BBB development and 
integrity as well. Braniste et al. demonstrated that gut microbiota influences the regulation of 
the BBB through epigenetic control of tight junction expression in CNS endothelial 
cells[57]. Emerging studies have demonstrated that an organism’s microbiota influences 
many physiological functions, including behavior[58]. Furthermore, gut microbiota has been 
reported to influence tissue barrier systems[59]. Comparing pathogen-free (control) and 
germ-free mice (altered microbiota), these authors discovered that germ-free mice display 
BBB dysfunction in both embryonic development and postnatal life, due to downregulation 
of tight junction protein expression. Indeed, unlike pathogen-free mice, germ-free mice 
display extravasation of Evans blue dye. Consistent with low tight junction expression, 
ultrastructure analysis by EM revealed disruption of tight junction complexes. Remarkably, 
transplanting fecal matter from pathogen-free mice to recolonize the intestinal microbiota of 
germ-free mice can restore the dysfunctional BBB observed in germ-free adult mice. Indeed, 
germ-free mice with recolonized microbiota have restored tight junction protein expression 
in the CNS with accompanying restriction of dye tracers to CNS endothelium. The 
molecular determinants from microbiota impacting BBB integrity in these experiments were 
short-chain fatty acids such as butyrate, which has been reported to strengthen the integrity 
of the intestinal epithelial barrier. Indeed, treatment with butyrate was sufficient to elevate 
tight junction protein expression and restore the BBB integrity in the germ-free mice. The 
authors suggest that butyrate epigenetically regulates tight junction expression in the CNS 
by increasing histone acetylation. This crosstalk between microbiota and the BBB is 
intriguing and provocative. It will be interesting to explore if short chain fatty acids directly 
increase BBB integrity or cause secondary effects on other signaling pathways throughout 
the body. Furthermore, it will be of clinical interest to explore how the use of strong 
antibiotics that eliminate gut microbiota influences the BBB.
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Another recent study highlighted how foreign microbes impact the BBB. Acute bacterial 
meningitis is an infection in the CNS that causes neural damage and can result in mental 
impairment, seizures, paralysis and death if untreated[60]. To induce meningitis, bacteria 
must first breach the BBB[61]. However, it is unclear how bacteria penetrate through the 
BBB. Kim et al. demonstrated that blood-borne bacteria such as group B Streptococcus 
(GBS) can weaken BBB integrity by upregulating the expression of Snail1, a zinc finger 
transcription factor, in host CNS endothelial cells that subsequently suppresses tight junction 
protein expression[62]. Exposure of GBS to CNS endothelial cells in vitro and in vivo 
upregulates Snail1 expression and downregulates tight junction protein expression, with 
accompanying increases in GBS counts in the brain. Furthermore, transgenic dominant-
negative Snai1 zebrafish are more resistent to GBS-mediated lethality. It is interesting that 
bacteria can manipulate the gene expression in host CNS endothelial cells to weaken the 
integrity of the BBB. It will be of clinical interest for future studies to explore what bacterial 
molecules interact with host CNS endothelial cells to alter gene expression and to determine 
if bacteria breach the BBB via weakened tight junctions.
Future directions of BBB research
Although the BBB research community has recently made significant strides in identifying 
novel molecular regulators and inductive signals that mediate BBB function and integrity, 
the field is still in its infancy, with many fundamental questions waiting to be answered 
(Box 2). Further refinements in cell type purification techniques and next-generation 
sequencing technologies will unravel key molecular regulators and core pathways essential 
for BBB formation and function. Currently, only a single CNS endothelial cell RNAseq 
dataset from mouse exists but nevertheless has been fruitful to compare gene expression 
among multiple purified cell types in the CNS[63]. However, this dataset is limited because 
it is only from normal developing mice at age P7. The RNAseq approach to unravel the 
transcriptome of BBB and other purified cell types in the NVU at different developmental, 
physiological, aging and disease contexts will address many questions about BBB 
regulation. Next-generation sequencing will be invaluable to address the underappreciated 
heterogeneity of the BBB. For example, different brain regions use different Wnt/ β-catenin 
molecular components for BBB function. Norrin is the Wnt signal in the retina and 
cerebellum whereas Wnt 7a/7b are the signals in the forebrain. [33]. Furthermore, it would 
interesting to explore how the molecular signatures of the CNS endothelial cells in 
circumventricular organs (the regions in the CNS that do not display BBB such as median 
eminence) differ from CNS endothelial cells displaying BBB[64–66].
Transcriptomics has proven invaluable in identifying genes that regulate BBB function and 
integrity[67]. But the genes from these datasets are still merely candidates until validated 
that they indeed mediate BBB regulation. Therefore, the field needs high-throughput 
screening to not only validate candidate genes but also to discover drugs that can modulate 
BBB permeability. The advent of genome editing methods such as CRISPR-Cas9 has 
facilitated the generation of in vivo loss-of-function transgenesis but this process is still 
arduous and too low throughput to validate a list of candidates from transcriptomics 
datasets[68]. Thus, the use of more tractable model organisms with simpler BBB and robust 
loss-of-function genetic manipulations could accelerate validation of candidates.
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The ideal high-throughput screening method would be an in vitro BBB system that 
reproduces the properties of the BBB in vivo, such as CNS endothelial cell polarity and 
restrictive paracellular and transcellular permeability. Because the functional BBB requires 
the interaction among the multiple cell types of the NVU, CNS endothelial cells readily lose 
their BBB properties ex vivo[69]. Several studies demonstrated that co-culture with 
astrocytes and pericytes to mimic the NVU can enhance BBB properties in endothelial cells 
[70]. Furthermore, stimulation of cultured endothelial cells with Wnt and Shh is sufficient to 
induce BBB properties without the need to co-culture other cell types, suggesting that 
activating core BBB pathways is sufficient to elicit BBB properties, and further emphasizing 
the need to determine the molecular regulators of BBB function activated by these signaling 
pathways[55,71]. Intriguingly, studies reported that human pluripotent stem cells treated 
with retinoic acid can differentiate to endothelial cells displaying BBB properties[72,73]. 
The development of these new technologies will accelerate the discoveries of key molecules 
and essential signaling pathways in BBB and neuroscience research
Although the BBB field has made significant progress in identifying key molecules that 
mediate BBB function, the molecular and cellular mechanisms of how these molecules are 
mediating BBB function and integrity are still poorly understood. This gap in knowledge is 
partly due to the limitations in the current technologies for BBB research. Currently, EM 
analyses in conjunction with dye tracers are the main techniques to monitor BBB 
properties[27]. But these techniques only provide a static snapshot of the BBB and do not 
provide essential information such as kinetics of vesicular trafficking. There is a pressing 
need to develop an in vivo high-resolution technique to monitor BBB properties such as 
tight junction complexes and transcytosis in real time.
A comprehensive understanding of the molecular constituents and mechanisms of BBB 
function and integrity would offer novel strategies for CNS therapeutics. Although the 
functional BBB is essential for proper neuronal function, the restrictive BBB is an 
impediment to deliver therapeutics, including recombinant proteins, antibodies and even 
small molecules, to the brain parenchyma[74]. Thus, a major focus of BBB research is 
identifying strategies to enhance delivery of therapeutics across the BBB. Here, we will 
highlight three promising methods to manipulate BBB properties to deliver drugs. First, 
several groups have demonstrated that hijacking receptor-mediated transcytosis pathways 
could deliver large, genetically engineered proteins across barrier endothelium[74]. The 
transferrin receptor (TfR), which binds to its ligand transferrin-bound iron and undergoes 
clathrin-mediated transcytosis to facilitate iron delivery to the brain, has been the main 
target of this work[75,76]. For example, chimeric monoclonal antibodies with α-Tfn fused 
to α-Aβ antibodies has been successful in hijacking the TfR pathway to reduce Aβ in an 
Alzheimer’s disease mouse model [77]. Second, scanning ultrasound (SUS), in which 
systemic injected circulating microbubbles causes transient opening of tight junctions when 
activated with ultrasound, has been reported to safely and transiently permeabilize the 
BBB[78,79]. Third, as we identify mediators of BBB function and better understand the 
molecular and cellular pathway underlying BBB regulation, we could target and manipulate 
these genes to enhance therapeutic delivery. For example, functional blocking of Frizzled4 
antibodies has been shown to permeabilize the blood-retina barrier, offering a temporal 
opportunity for enhanced drug delivery[80]. As we further understand the cellular pathways 
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and molecular mechanisms that regulate BBB function and integrity, we can develop 
creative strategies to manipulate these molecules to enhance drug delivery. Answering 
fundamental questions in BBB research and identifying molecular constituents of barrier 
regulation will enhance the development of therapeutics to modulate the BBB for drug 
delivery and neurologic disorders.
Concluding remarks
The BBB is comprised of specialized CNS endothelial cells that regulate CNS homeostasis 
to ensure proper neuronal function. In this review, we have highlighted that improvements in 
experimental tools have facilitated the recent findings of molecular constituents that mediate 
BBB function and integrity. These discoveries have greatly expanded our molecular and 
cellular understanding of this specialized vasculature that has fascinated physiologists for 
more than a century. Nevertheless, these discoveries open many more fundamental questions 
waiting to be resolved. We have emphasized the pressing demand for refinement in 
experimental technologies that will certainly accelerate our discoveries for novel molecules 
and our understanding of their cellular mechanisms that mediate BBB function. We believe 
that these findings will directly benefit therapeutics for neurological disorders in both drug 
delivery and repairing the dysfunctional barrier in certain neurological diseases.
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Glossary
Angiogenesis the development of new vessels from proliferation of pre-existing 
endothelial cells.
Blood-brain barrier a physiological barrier comprised of a thin layer of continuous, 
non-fenestrated CNS endothelial cells that regulates the brain 
microenvironment for proper neuronal function.
Endothelial cells mesoderm derived cells that line vasculatures of the circulatory 
system.
Immune Privilege introduction of antigens without eliciting an inflammatory 
adaptive immune response.
Neurovascular Unit the functional interactions among neurons, glia, pericytes and 
endothelial cells.
Tight Junctions a junctional complex between two cells that is essential for cell 
polarity, barrier functions, and cell adhesions.
Transcytosis Vesicular trafficking from the luminal to the abluminal plasma 
membrane and vice-versa.
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• The blood-brain barrier (BBB) is comprised of CNS endothelial cells that 
display specialized molecular properties essential for BBB function and 
integrity.
• These molecular BBB properties are not intrinsic to CNS endothelial cells but 
have to be induced by the environment.
• The formation, function and maintenance of the BBB require the functional 
interaction between CNS endothelial cells and the neurovascular units (NVU).
• Advances in gene profiling and cell-type purification methods have progressed 
the identification of molecular mediators and core cellular pathways involved in 
BBB function and integrity.
• A comprehensive understanding of key molecules and cellular pathways 
involved in BBB function would offer novel strategies for CNS therapeutics.
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• What are the repertoires of molecules and genetic programs that mediate BBB 
formation and function? Cell type–specific purification methods and gene 
profiling have facilitated recent strides in elucidating molecular mediators and 
cellular pathways that confer CNS endothelial cells with fundamental BBB 
properties. Therefore, improvement in these experimental techniques such as 
using highly sensitive, unbiased, and high-throughput next generation 
sequencing technologies will unravel key molecular regulators and core 
pathways essential for the BBB.
• What are the minimal core components necessary for endothelial cells in vitro to 
recapitulate the BBB properties displayed in vivo? Recent studies have 
demonstrated that activation of Wnt or Shh signaling is sufficient to elevate 
certain BBB properties in endothelial cells in vitro. A robust BBB in vitro 
system would be essential for high-throughput screening of drugs that can 
modulate the permeability of the BBB.
• What are the molecular and cellular mechanisms of how these key molecules 
mediate BBB properties?
• How tightly coupled is the relationship between CNS angiogenesis and 
barriergenesis? These two developmental processes may be more independent 
than once appreciated, especially with emerging studies demonstrating a) that 
CNS angiogenesis continues well after barriergenesis and throughout postnatal 
life and b) the identity of genes that specifically regulate barriergenesis 
independent of angiogenesis such as Mfsd2a.
• How can we target the molecular regulators of BBB function to manipulate 
BBB properties for delivery of therapeutics? A major focus in BBB research has 
targeted the transferrin receptor to hijack clathrin mediated transcytosis for the 
delivery of therapeutics.
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Figure 1. The functional BBB is dependent on the neurovascular unit
The blood-brain barrier (BBB) is localized at central nervous system (CNS) microvessels, 
comprising of a single layer of continuous, nonfenestrated endothelial cells. Surrounding the 
aluminal surface of the CNS endothelial cells are the basement membrane, pericytes, and 
astrocyte endfeet, collectively known as the neurovascular unit (NVU). The BBB properties 
are not intrinsic to CNS endothelial cells but require the continuous functional interactions 
with the NVU.
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Figure 2. The four fundamental molecular properties of CNS endothelial cells that contribute to 
BBB integrity and function
(1) Specialized tight junction complexes between endothelial cells prevent paracellular flux. 
(2) CNS endothelial cells have low rates of transcytosis, limiting transcellular flux. (3a) 
CNS endothelial cells mediate the selective uptake of nutrients and molecules from the 
blood using selective influx transporters and (3b) efflux of toxins against their concentration 
gradient with ATP-dependent selective efflux transporters. (4) The low expression of 
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leukocyte adhesion molecules (LAMs) contributes to the low level of immune surveillance 
in the CNS.
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Yes Yes Yes** (25–27) (36)
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Yes Yes Yes** (25–27)
(29) (32)
Astrocytes ND Yes ND (47)
Gut Microbiota No Yes ND (49)
*
No vascular defects were observed during embroynic analysis of LSR knockout mice
**
Loss-of-function of Wnt signaling results in elevated expression of PLVAP, a marker for fenestarted endothelial cells and transcytosis
***
Although ultrastructural analysis by EM revealed no defects in tight junction complexes, loss of LSR affects tight junctions
ND: Not Determined
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